newsfilter
← Latest News
Business Wire·

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study – -- Manufacturing Process Enhancements Expected to Further Improve